Loading...

HSIC: Earnings Momentum From Automation And E-Commerce Will Shape Outlook

Published
25 Aug 24
Updated
20 Nov 25
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
-2.8%
7D
6.9%

Author's Valuation

US$771.9% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Last Update 20 Nov 25

Fair value Increased 2.46%

HSIC: Operational Improvements and Automation Are Expected to Support Earnings Momentum

Analysts have increased their price target for Henry Schein from $75 to $77, citing expectations for moderate improvements in revenue growth and future earnings. They also pointed to optimism driven by recent operating performance and strategic initiatives.

Analyst Commentary

Recent research from Wall Street has provided insight into the varied perspectives on Henry Schein’s financial outlook. Analysts cite both positive and cautionary factors underpinning the stock’s current valuation and future performance.

Bullish Takeaways

  • Optimism is driven by initiatives in automation and the launch of a new global e-commerce platform. These moves are expected to streamline operations and contribute to sustained earnings growth.
  • Improved salesforce efficiency and a favorable product mix could translate into notable operating margin expansion. Projections indicate up to 400 basis points of improvement.
  • Analysts anticipate that these operational enhancements may drive at least $7 in earnings per share by 2027, which is well above current targets.
  • A strong third-quarter performance has instilled confidence in near-term financial results. This supports the potential for upward revisions in consensus estimates.

Bearish Takeaways

  • Despite recent gains, some analysts express concerns about the stock's ability to break out from its historically defined trading range.
  • Cautious analysts emphasize the lack of a clear catalyst for further upside beyond the recent positive earnings surprise.
  • Questions remain regarding the sustainability of margin improvements, especially if operational efficiencies take longer to materialize than projected.
  • Valuation remains a central topic. Some on the Street argue that much of the anticipated growth is already priced into the shares.

What's in the News

  • VideaHealth, in collaboration with Henry Schein One, launched the Impact Panel. This AI-powered enhancement for Dentrix users aims to improve patient education and case acceptance by integrating real-time AI findings and interactive educational tools into dental workflows (Key Developments).
  • Henry Schein, Inc. raised its 2025 guidance and now expects total sales growth of approximately 3% to 4% over 2024, up from the previous range of 2% to 4% (Key Developments).
  • The company completed a major tranche of its share repurchase program. It bought back over 3.3 million shares for $228.92 million; total buybacks now represent 29% of outstanding shares since 2018 (Key Developments).
  • Henry Schein Medical expanded its SolutionsHub by partnering with Colaborate, a consulting firm that supports independent and hospital-based labs with compliance, efficiency, and sustainability services (Key Developments).
  • Biomerica, Inc. entered a marketing partnership with Henry Schein to distribute the inFoods IBS diagnostic test in the U.S. (excluding New York), leveraging Henry Schein's extensive nationwide sales network (Key Developments).

Valuation Changes

  • Consensus Analyst Price Target has increased from $75.15 to $77.00, reflecting a moderate upward revision in fair value estimates.
  • Discount Rate has risen slightly, moving from 6.78% to 6.96%. This may suggest a marginally higher risk or cost of capital assumption.
  • Revenue Growth projection has edged up from 3.62% to 3.64% annually. This indicates incremental optimism about future sales momentum.
  • Net Profit Margin projection has declined from 4.45% to 4.09%, signaling updated expectations for slightly lower profitability.
  • Future P/E ratio estimate has increased from 14.43x to 16.00x, highlighting a higher multiple placed on expected earnings.

Key Takeaways

  • Focus on high-margin segments, digital transformation, and operational efficiencies is expected to boost margins and earnings growth.
  • Demographic shifts and industry consolidation are likely to drive sustained demand and enhance customer loyalty in key markets.
  • Margin pressures from competitive pricing, staffing constraints, regulatory hurdles, and execution risks could limit revenue growth and profitability despite stabilization efforts in key business areas.

Catalysts

About Henry Schein
    Provides health care products and services to office-based dental and medical practitioners, and alternate sites of care worldwide.
What are the underlying business or industry changes driving this perspective?
  • The company is experiencing strong growth in high-margin businesses such as Specialty Products, Technology, and private-label offerings, and expects over 50% of non-GAAP operating income to come from these segments-supporting structurally higher gross margins and likely driving earnings expansion.
  • Investments in digital workflow, AI solutions, and integrated cloud-based practice management platforms are accelerating recurring SaaS revenues and client retention, positioning Henry Schein to benefit from the ongoing digital transformation of healthcare, which should support both revenue growth and improved margins.
  • Henry Schein is actively pursuing operational efficiencies-including $100M+ cost savings run-rate by end of 2025 and further value creation initiatives led by KKR's Capstone-which are expected to lower operating expenses and drive net margin improvement from 2026 onward.
  • Continued expansion of the company's Home Solutions platform to meet increased demand for at-home healthcare, coupled with robust demographic drivers from an aging global population, are anticipated to support sustained volume growth in core distribution and specialty lines, providing a foundation for long-term revenue growth.
  • Dental and medical practice consolidation is increasing client reliance on integrated supply, technology, and value-added service partners like Henry Schein, enhancing share gains and customer stickiness across both the U.S. and international markets-with positive implications for top-line growth and earnings stability.

Henry Schein Earnings and Revenue Growth

Henry Schein Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?
  • Analysts are assuming Henry Schein's revenue will grow by 4.0% annually over the next 3 years.
  • Analysts assume that profit margins will increase from 3.0% today to 4.3% in 3 years time.
  • Analysts expect earnings to reach $614.4 million (and earnings per share of $4.67) by about September 2028, up from $389.0 million today.
  • In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 16.1x on those 2028 earnings, down from 21.1x today. This future PE is lower than the current PE for the US Healthcare industry at 21.0x.
  • Analysts expect the number of shares outstanding to decline by 2.74% per year for the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 6.78%, as per the Simply Wall St company report.

Henry Schein Future Earnings Per Share Growth

Henry Schein Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?
  • Persistent competitive pricing pressures, especially in key categories like gloves (where pricing remains very competitive and still below previous year levels), could continue to weigh on distribution gross margins, reducing profitability and potentially hindering earnings growth even as volume stabilizes.
  • Flat to modest dental patient traffic and ongoing staffing shortages (notably in hygienists and office support) are constraining underlying volume growth in the core dental business globally, which limits organic revenue expansion and exposes results to macroeconomic or reimbursement shocks in key markets.
  • Greater customer price sensitivity due to tariffs and the potential for large DSO/group customers to actively RFP portions of their business places greater bargaining power with customers, risking margin compression and slower top-line growth if Henry Schein cannot fully offset price concessions with its owned brands or value-added services.
  • International expansion, while producing some bright spots, faces country-specific regulatory challenges (e.g. recent law changes in France), currency volatility, and localized competition, all of which could restrict anticipated revenue diversification and net earnings contribution from outside the U.S.
  • The multi-year leadership transition and implementation of cost-saving/value creation initiatives with KKR/consulting partners carry significant execution risk; delays, integration hurdles, or cultural disruption could impair near-term efficiency gains, and if technology or AI investments lag or under-deliver, Henry Schein could lose share to more innovative or nimble competitors, pressuring long-term earnings growth.

Valuation

How have all the factors above been brought together to estimate a fair value?
  • The analysts have a consensus price target of $73.231 for Henry Schein based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $83.0, and the most bearish reporting a price target of just $55.0.
  • In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $14.4 billion, earnings will come to $614.4 million, and it would be trading on a PE ratio of 16.1x, assuming you use a discount rate of 6.8%.
  • Given the current share price of $67.65, the analyst price target of $73.23 is 7.6% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives